U.S. Diabetes Pipeline Outlook

Frost & Sullivan
November 22, 2006
72 Pages - SKU: MC1391206
License type:
Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
5/11/2012 | published by: Kalorama Information
The drug discovery process is long, arduous and costly, which has driven outsourcing in this field. The first phase is discovery of a lead compound, a molecule that affects biological function by binding to a  |  more...
$3,995.00
Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity
5/15/2012 | published by: GBI Research
Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity Summary GBI Research, the leading  |  more...
$3,500.00
Freedonia Focus on Diabetes Monitoring Products: United States
5/31/2012 | published by: Freedonia Focus
This report discusses US demand for diabetes monitoring products for the years 2006 and 2011, with forecasts for 2016. Topics covered include market size, product and market segmentation, regulatory considerations, product development, market environment, product  |  more...
$600.00
Targeted Health and Wellness Foods and Beverages: The U.S. Market and Global Trends
3/1/2012 | published by: Packaged Facts
The market for targeted health and wellness foods and beverages is a dynamic and promising one, driven largely by the growing recognition—among scientists, government, practitioners, and consumers alike—of the instrumental role diet plays in a  |  more...
$3,500.00
Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules
4/30/2012 | published by: GBI Research
Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules Summary GBI Research, the leading business intelligence provider, has released its latest research  |  more...
$3,500.00
Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments
4/30/2012 | published by: GBI Research
Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments Summary GBI Research, the leading business intelligence provider, has released its latest  |  more...
$3,500.00
Clinical Trials Market in India 2012
4/13/2012 | published by: Netscribes (India) Pvt. Ltd.
The Indian clinical trials market is growing at an excellent rate and currently witnessing a large number of global pharmaceutical companies outsourcing trials to contract research organizations (CROs) in India. This is largely due to  |  more...
$795.00
Oral Drug Delivery Market to 2017 - Out-licensing Proprietary Technologies for Proteins, Peptides and Small Molecules to Drive Revenue Growth
4/30/2012 | published by: GBI Research
Oral Drug Delivery Market to 2017 - Out-licensing Proprietary Technologies for Proteins, Peptides and Small Molecules to Drive Revenue Growth Summary GBI Research, the leading business intelligence provider, has released its latest research “Oral Drug Delivery Market  |  more...
$3,500.00
Orphan Disease Therapeutics Market to 2018 - Improved Understanding of Rare Diseases' Heterogeneity and Novel New Clinical Trial Designs to Foster Innovation
4/30/2012 | published by: GBI Research
Orphan Disease Therapeutics Market to 2018 - Improved Understanding of Rare Diseases' Heterogeneity and Novel New Clinical Trial Designs to Foster Innovation Summary GBI Research, the leading business intelligence provider, has released its latest research “Orphan Disease  |  more...
$3,500.00
Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion
4/30/2012 | published by: GBI Research
Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion Summary GBI Research, the leading business intelligence provider, has released its latest research, “Cytotoxic Therapies Market  |  more...
$3,500.00